These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 2381621)

  • 1. CA 125 levels in menopausal women.
    Westhoff C; Gollub E; Patel J; Rivera H; Bast R
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):428-31. PubMed ID: 2381621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing serum CA 125 levels in normal women.
    Grover S; Quinn MA; Weideman P; Koh H
    Obstet Gynecol; 1992 Apr; 79(4):511-4. PubMed ID: 1553167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of variability in normal CA 125 levels.
    Westhoff C; Levin B; Ladd G; O'Connor J
    Cancer Epidemiol Biomarkers Prev; 1992; 1(5):357-9. PubMed ID: 1305467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
    Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
    Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
    Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.
    Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS
    Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
    Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
    Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of CA 72.4 in maternal serum and amniotic fluid.
    Tayyar M; Tutus A
    J Perinat Med; 1998; 26(5):400-3. PubMed ID: 10027137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CA 125 in diagnosis and prognosis of epithelial ovarian cancer].
    Cohen AD; Piura B; Cohen Y; Shoenfeld Y
    Harefuah; 1994 Mar; 126(5):283-5, 303. PubMed ID: 8188111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA-125 measurements > 65 U/mL. Clinical value.
    Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
    J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
    Menczer J; Ben-Baruch G; Moran O; Lipitz S
    Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P; Azen C; Lopez E; Platt LD; Karlan BY
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences with the cancer marker CA 125 in gynecologic diseases].
    Pilgrim G; von Broen B; Johannsmeyer KD
    Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses.
    Finkler NJ; Benacerraf B; Lavin PT; Wojciechowski C; Knapp RC
    Obstet Gynecol; 1988 Oct; 72(4):659-64. PubMed ID: 3047614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX; Schwartz PE; Li XG; Yang Z
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.